A week-48 randomized phase-3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients

OBJECTIVES: To investigate efficacy and safety of a single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg vs. darunavir/cobicistat plus emtricitabine/tenofovir disoproxyl fumarate (TDF) (control) in antiretroviral-treatment-naive, HIV-1-infec...

Descripción completa

Detalles Bibliográficos
Autores principales: Eron, Joseph J., Orkin, Chloe, Gallant, Joel, Molina, Jean-Michel, Negredo, Eugenia, Antinori, Andrea, Mills, Anthony, Reynes, Jacques, Van Landuyt, Erika, Lathouwers, Erkki, Hufkens, Veerle, Jezorwski, John, Vanveggel, Simon, Opsomer, Magda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039393/
https://www.ncbi.nlm.nih.gov/pubmed/29683855
http://dx.doi.org/10.1097/QAD.0000000000001817

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6039393/
https://www.ncbi.nlm.nih.gov/pubmed/29683855
http://dx.doi.org/10.1097/QAD.0000000000001817

Ejemplares similares